Nature Biotechnology 2003 - Abstracts
| Nature Biotechnology 2003 | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. | Business | Pierre Chambon, Frank Schnutgen, Nathalie Doerflinger, Cecile Calleja, Olivia Wendling, Norbert B. Ghyselinck | |||
| A framework for designing transgenic crops--science, safety and citizen's concerns. | Business | Ariane Konig | |||
| A genetic approach to inactivating chemokine receptors using a modified viral protein. | Business | V. McNeil Coffield, Qi Jiang, Lishan Su | |||
| A method for the comprehensive proteomic analysis of membrane proteins.(Cover Story) | Business | John R. Yates III, Christine C. Wu, Michael J. MacCoss, Kathryn E. Howell | |||
| Analyzing antibody specificity with whole proteome microarrays. | Business | Michael Snyder, Gregory A. Michaud, Michael Salcius, Fang Zhou, Jaclyn Bonin, Hong Guo, Paul F. Predki, Barry I. Schweitzer | |||
| An archael endoribonuclease catalyzes cis- and trans-nonspliceosomal splicing in mouse cells. | Business | Giancarlo Deidda, Nicoletta Rossi, Glauco P. Tocchini-Valentini | |||
| An engineered multidomain bacterial peptide as a model for targeted antibiotics against specific bacteria. | Business | Zhang Jie, Xiao-Qing Qiu, Xiao-Fong Lu, Su-Hua Zhang, He Wang, Sheng-Fu Li, Gang Cheng, Lin Wan, Li Yang, Jun-Yong Zuo, Yu-Qi Zhou, Hai-Yun Wang, Xin Cheng, Zheng-Rong Ou, Zi-ChengZhang Zhong, Zi-Cheng Zhong | |||
| Antibiotic optimization via in vitro glycorandomization. | Business | Xun Fu, Christoph Albermann, Jiqing Jiang, Jianchun Liao, Changsheng Zhang, Jon S. Thorson | |||
| Antisense starts making more sense. | Business | Gordon G. Carmichael | |||
| Approaches for the sequence-specific knockdown of mRNA. | Business | John J. Rossi, Lisa J. Scherer | |||
| A transformation method for obtaining marker-free plants of a cross-pollinating and vegetatively propagated crop. | Business | Nick de Vetten, Anne-Marie Wolters, Krit Raemakers, Ingrid van der Meer, Renaldo ter Stege, Els Heeres, Paul Heeres, Richard Visser | |||
| Bacterial batteries. | Business | Uwe Schroder, Fritz Scholz | |||
| Biobusiness on the web.(includes related article) | Business | Robert M. Frederickson | |||
| Biomedical informatics for proteomics. | Business | Mark S. Boguski, Martin W. MacIntosh | |||
| Biotech awaits single European financial market. | Business | Sabine Louet | |||
| Biotechnology and the UN's millennium development goals. | Business | Peter A. Singer, Tara Acharya, Abdallah S. Daar | |||
| Biotechs await IPO 'boomlet'. | Business | Pete Mitchell | |||
| Breathing new life into insect-resistant plants. | Business | William J. Moar | |||
| Bt-resistance management-theory meets data.(Bacillus thuringiensis) | Business | Fred Gould | |||
| Cloning by numbers. | Business | Louis-Marie Houdebine | |||
| Commercializing nanotechnology. | Business | Laura Mazzola | |||
| Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis.(Cover Story) | Business | Jun Ishikawa, Yoshiyuki Sakaki, Masahira Hattori, Haruo Ikeda, Akiharu Hanamoto, Mayumi Shinose, Hisashi Kikuchi, Tadayoshi Shiba, Satoshi Omura | |||
| Computational discovery of gene modules and regulatory networks. | Business | Tong Ihn Lee, Richard A. Young, Nicola J. Rinaldi, David K. Gifford, Tommi S. Jaakkola, Ziv Bar-joseph, Georg K. Gerber, Jane Y. Yoo, Francois Robert, D. Benjamin Gordon, Ernest Fraenkel | |||
| Concerns over refuge size for US EPA-approved Bt corn.(transgenic corn: Bacillus thuringiensis, includes related article) | Business | Kendall Powell | |||
| Continuous high-titer HIV-1 vector production. | Business | Mary Collins, Yasuhiro Ikeda, Yasuhiro Takeuchi, Francisco Martin, Francois-Loic Cosset, Kyriacos Mitrophanous | |||
| Converging science and technology at the nanoscale: opportunities for education and training. | Business | Mihail C. Roco | |||
| Crystal gazing in optical microscopy. | Business | Scott E. Fraser | |||
| Design of multivalent complexes using the barnase-barstar module. | Business | Sergey M. Deyev, Robert Waibel, August P. Schubiger, Andreas Pluckthun | |||
| Disease proteomics. | Business | Sam Hanash | |||
| E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. | Business | Gabriel Brooks, David Kirn, Richard Hill, Yaohe Wang, Gunnel Hallden, Arthi Anand, Ta-Chiang Liu, Jennelle Francis, Nick Lemoine | |||
| Electricity generation by direct oxidation of glucose in mediatorless microbial fuel cells.(Rhodoferax ferrireducens ) | Business | Derek R. Lovley, Swades K. Chaudhuri | |||
| Electrochemical DNA sensors. | Business | Jacqueline K. Barton, T Gregory Drummond, Michael G. Hill | |||
| EMEA struggles with need to restructure.(European Agency for the Evaluation of Medicinal Products ) | Business | Cormac Sheridan | |||
| Engineering the mouse genome with bacterial artificial chromosomes to create multipurpose alleles. | Business | Youming Zhang, W.W.M. Pim Pijnappel, Giuseppe Testa, Kristina Vintersten, Vladimir Benes, A Francis Stewart, Austin G. Smith, Andrew J.H. Smith, Chambers; Ian | |||
| Engineering what comes naturally.(tissue engineering) | Business | John M. Wozney, Rebecca H. Li | |||
| Enhancement of therapeutic protein in vivo activities through glycoengineering. | Business | Steve Elliott, Janis Fuller, Geri Trail, David Chang, Leigh Busse, Lynette Buck, David Brankow, Ken Aoki, Sheilah Asher, Tony Lorenzini, James Grant, Natasha Hernday, Martha Hokum, Sylvia Hu, Andrew Knudten, Nancy Levin, Renee Komorowski, Frank Martin, Rachell Navarro, Timothy Osslund, Gary Rogers, Norma Rogers, Joan Egrie | |||
| Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. | Business | Robert D. Rosenberg, Balagurunathan Kuberan, Miroslaw Z. Lech, David L. Beeler, Zhengliang L. Wu | |||
| Errors in patent application sequence listings. | Business | Robert Jones | |||
| EU wrangles internally over safety of donated tissues and cells.(European Union) | Business | Peter Vermij | |||
| Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. | Business | Joel Vandekerckhove, Kris Gevaert, Marc Goethais, Lennart Martens, Jozef Van Damm, An Staes, Gregoire R. Thomas | |||
| Fabrication of novel biomaterials through molecular self-assembly. | Business | Shuguang Zhang | |||
| Fighting company spin. | Business | Trevor M. Fenning, Jonathan Gershenzon | |||
| First Parkinson gene therapy trial launches. | Business | Ken Howard | |||
| Fluorescent proteins with ties that bind. | Business | Timothy A. Ryan | |||
| Fluorobodies combine GFP fluorescence with the binding characteristics of antibodies.(Generic Framing Procedure) | Business | Ahmet Zeytun, Andreas Jeromin, Bethe A. Scalettar, Geoffrey S. Waldo, Andrew RM Bradbury | |||
| FRET imaging. | Business | Elizabeth A. Jares-Erijman, Thomas M. Jovin | |||
| From genomics to proteomics. | Business | Matthias Mann, Mike Tyres | |||
| From words to literature in structural proteomics. | Business | Andrej Sali, Wolfgang Baumeister, Robert Glaeser, Thomas Earnest | |||
| Gene medication or genetic modification? the devil is in the details. | Business | Grethe S. Foss, Sissel Rogne | |||
| Genetically targeted chromophore-assisted light inactivation. | Business | Oded Tour, Rene M. Meijer, David A. Zacharias, Roger Y. Tsien | |||
| Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. | Business | Joan E. Smallshaw, Victor Ghetie, Jose Rizo, John R. Fulmer, Linda L. Trahan, Maria-Ana Ghetie, Ellen S. Vitetta | |||
| Genomic scale profiling of nutrient and trace elements in Arabidopsis thaliana. | Business | Lauren McIntyre, Julian I. Schroeder, David E. Salt, Brett Lahner, Jiming Gong, Mehrzad Mahmoudian, Elizabeth E. Rogers, Mary L. Guerinot, Jeffrey F. Harper, John M. Ward | |||
| Germany biotech gets second chance. | Business | Cormac Sheridan | |||
| Human antibodies from immunized donors are protective against anthrax toxin in vivo. | Business | Mark R. Wallace, Katherine S. Bowdish, John D. Malone, Martha A. Wild, Hong Xin, Toshiaki Maruyama, Mary Jean Nolan, Peter M. Calveley | |||
| Identification of anti-repressor elements that confer high and stable protein production in mammalian cells. | Business | Ted H.J. Kwaks, Phil Barnett, Wieger Hemrika, Tjalling Siersma, Richard G.A.B. Sewalt, David P.E. Satijn, Janynke F. Brons, Rik van Blokland, Paul Kwakman, Arle L. Kruckeberg, Angele Keider, Arie P. Otte | |||
| Identification of co-regulated genes through Bayesian clustering of predicted regulatory binding sites. | Business | William Thompson, Zhaohui S. Qin, Lee Ann McCue, Linda Mayerhofer, Charles E. Lawrence, Jun S. Liu | |||
| Immunofluorescence stimulated emission depletion microscopy. | Business | Marcus Dyba, Stefan Jakobs, Stefan W. Hell | |||
| Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. | Business | Steven M. Albelda, G. Alexander Patterson, Benjamin D. Kozower, Melpo Christofidou-Solomidou, Silvia Muro, Thomas D. Sweitzer, Donald G. Buerk, Charalambos C. Solomides, Vladimir R. Muzykantov | |||
| Indian biogenerics industry emerges. | Business | K.S. Jayaraman | |||
| Insect resistance conferred by 283-kDa Photorhabdus luminescens protein TcdA in Arabidopsis thaliana. | Business | Dong Liu, Stephanie Burton, Todd Glancy, Ze-Sheng Li, Thomas Meade, Ronnie Hampton, Donald J. Merlo | |||
| Integrated nanoliter systems. | Business | Jong Wook Hong, Stephen R. Quake | |||
| Integrating intellectual property within the organizational social structure. | Business | Iraj Daizadeh | |||
| Invention and commercialization in optical bioimaging. | Business | Daniel L. Farkas | |||
| Investing in nanotechnology. | Business | Robert Paull, Josh Wolfe, Peter Hebert, Michael Sinkula | |||
| Ion genomics. | Business | Philip A. Rea | |||
| Italy employs further GMO delay tactics.(Genetically modified organism) | Business | Anna Meldolesi | |||
| Jumping genes and containment. | Business | Henry Daniell, Christopher L. Parkinson | |||
| Large-scale genotyping of complex DNA. | Business | Urvashi Surti, Giulia C. Kennedy, Hajime Matsuzaki, Shoulian Dong, Wei-min Liu, Jing Huang, Guoying Liu, Xing Su, Manqiu Cao, Wenwei Chen, Jane Zhang, Weiwei Liu, Geoffrey Yang, Xiaojun Di, Thomas Ryder, Zhijun He, Michael S. Phillips, Michael T. Boyce-Jacino, Stephen PA Fodor, Keith W. Jones | |||
| Little science, big bucks. | Business | Laura DeFrancesco | |||
| Mass spectrometry-based proteomics. | Business | Matthias Mann, Ruedi Aebersold | |||
| Membrane proteins ride shotgun.(purpose of membrane proteins) | Business | Thierry Rabilloud | |||
| Mending the message. | Business | Mariano A. Garcia-Blanco | |||
| Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers.(BH3 interacting domain death agonist) | Business | Christopher D. Richardson, Jurgen Ruland, Eric C. Hsu, Belinda Hsi, Masami Hirota-Tsuchihara, Cathy Iorio, Farida Sarangi, Jingyu Diao, Giovanni Migliaccio, D. Lorne Tyrrell, Norman Kneteman | |||
| Multiherbicide tolerance conferred by AtPgp1 and apyrase overexpression in Arabidopsis thaliana. | Business | Brian Windsor, Alan Lloyd, Stanley J. Roux | |||
| Near-field optics: from subwavelength illumination to nanometric shadowing. | Business | Alina Strinkovski, Aaron Lewis, Hesham Taha, Alexandra Manevitch, Atrium Khatchatouriants, Rima Dekhter, Eric Ammann | |||
| New biotech hubs may emerge as industry matures. | Business | Paroma Basu | |||
| New paths to human ES cells?.(embryonic stem) | Business | Davor Solter | |||
| Nonlinear magic: multiphoton microscopy in the biosciences. | Business | Warren R. Zipfel, Rebecca M. Williams, Watt W. Webb | |||
| No room for experiment: the federal circuit's narrow construction of the experimental use defense. | Business | S. Peter Ludwig, Jason C. Chumney | |||
| Optical coherence tomography for ultrahigh resolution in vivo imaging. | Business | James G. Fujimoto | |||
| Phenotypic alteration of eukaryotic cells using randomized libraries of artificial transcription factors. | Business | Kyung-Soon Park, Dong-ki Lee, Hor Lee, Young-Soon Jang, Yong Ha Kim, Yang, Sung-Il Lee, Wongi Seol, Jin-Soo Kim | |||
| Press before paper-when media and science collide. | Business | Neal C. Stewart Jr | |||
| Product introduction. | Business | ||||
| Product introduction. | Business | ||||
| Professional master's degree programs in regulatory affairs and biomedical quality systems. | Business | Larry E. Gundersen, E. Dale Sevier, Robert Wang, A. Stephen Dahms | |||
| Protein analysis on a proteomic scale. | Business | Stanley Fields, Michael Snyder, Eric Phizicky, Philippe I.H. Bastiaens, Heng Zhu | |||
| Regulators equivocate on safety of clones. | Business | Kendall Powell | |||
| Repair of bone defects using synthetic mimetics of collagenous extracellular matrices.(Cover Story) | Business | Matthias P. Lutolf, Franz E. Weber, Hugo G. Schmoedel, Jason C. Schense, Thomas Kohler, Ralph Muller, Jeffrey A. Hubbell | |||
| Secon-harmonic imaging microscopy for visualizing biomolecular arrays in cells, tissues and organisms. | Business | Paul J Campagnola, Leslie M. Loew | |||
| Semisynthetic production of unnatural L-alpha-amino acids by metabolic engineering of the cysteine-biosynthetic pathway. | Business | Thomas H.P. Maier | |||
| Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. | Business | Michel Sadelain, Chad May, Mikhail Doubrovin, Julius Balatoni, Ronald Finn, Anna Ivanova, Richard J. O'Reilly, Isabelle Riviere, Guenther Koehne, Ekaterina Doubrovina, Pat Zanzonico, Humilidad F. Gallardo, Julie Teruya-Feldstein, Glen Heller, Vladimir Ponomarev, Shutian Ruan, Ronald G. Blasberg, William Bornmann, Steven M. Larson, Juri G. Gelovani Tjuvajev | |||
| Sialylated endogenous glycoconjugates in plant cells. | Business | Miti M. Shah, Kazuhito Fujiyama, C. Robert Flynn, Lokesh Joshi | |||
| Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis.(Cover Story) | Business | Chang-Deng Hu, Tom K. Kerppola | |||
| Site-specific gene targeting in mouse embryonic stem cells with intact bacterial artificial chromosomes. | Business | Yi Yang, Brian Seed | |||
| Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.(polyethylene glycol to protein, tumor necrosis factor) | Business | Yoko Yamamoto, Yasuo Tsutsumi, Yasuo Yoshioka, Toshihide Nishibata, Kyoko Kobayashi, Takayuki Okamoto, Yohei Mukai, Tomoe Shimizu, Shinsaku Nakagawa, Satoshi Nagata, Tadanori Mayumi | |||
| Slimy business-the biotechnology of biofilms. | Business | Beth Schachter | |||
| Small-scale systems for in vivo drug delivery. | Business | Robert Langer, David A. LaVan, Terry McGuire | |||
| Soft landing for protein chips. | Business | Michael P. Washburn | |||
| Synthesis of a poly (vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. | Business | Yoko Yamamoto, Yasuo Tsutsumi, Takayuki Okamoto, Shinsaku Nakagawa, Satoshi Nagata, Tadanori Mayumi, Haruhiko Kamada, Keiko Sato-Kamada, Yasuo Yoshioko | |||
| Taiwan: biotech vision. | Business | David Cyranoski | |||
| Taming ricin toxin. | Business | Robert J. Kreitman | |||
| Targeting cytokines to inflammation sites. | Business | Gill Adams, Sandrine Vessillier, Hanna Dreja, Yuti Chernajovsky | |||
| The biotechnology bubble machine. | Business | David Rasnick | |||
| The genome sequence of the entomopathogenic bacterium Photorhabdus luminescens. | Business | Noel Boemare, Sead Taourit, Philippe Glaser, Antoine Danchin, Alain Givaudan, Frank Kunst, Carmen Buchrieser, Sylviane Derzelle, Eric Duchaud, Christophe Rusniok, Lionel Frangeul, Stephanie Bocs, Caroline Boursaux-Eude, Michael Chandler, Jean-Francois Charles, Elie Dassa, Richard Derose, Georges Freyssiner, Sophie Gaudriault, Claudine Medigue, Anne Lanois, Kerrie Powell, Patricia Siguier, rachel Vincent, Vincent Wingate, Mohamed Zouine | |||
| The past, present, and future of biotechnology in Mexico.(Industry Overview) | Business | Lourival Possani | |||
| The patent gamble: strategic insights for playing the worldwide patent game. | Business | William A. Barrett | |||
| The potential enviromental impact of engineered nanomaterials. | Business | Vicki L. Colvin | |||
| The 'right' size in nanobiotechnology. | Business | George M. Whitesides | |||
| The rise of European venture capital for biotechnology. | Business | Michael Howell, Mark D. Dibner, Melanie Trull | |||
| Thermodynamics - old laws in medicine and complex disease.(Column) | Business | Richard Strohman | |||
| The rollercoaster ride to anti-cancer antibodies. | Business | Paul Carter, Louis M. Weiner | |||
| The set of embryo subjects.(includes related article)(Column) | Business | Louis M. Guenin | |||
| The Streptomyces genome - be prepared!(Cover Story) | Business | David A. Hopwood | |||
| Time to drop the language of 'consensus'. | Business | Leigh Turner | |||
| Toward an integrated biotechnological engineering education program: a Canadian perspective.(BioteCanada Annual Report 2002) | Business | Patrick Vermette, Pierre Proulx, Bernard Marcos | |||
| Toward fluorescence nanoscopy. | Business | Stefan W. Hell | |||
| Transgenic plants expressing two Bacillus thuringiensis toxins delay insect resistance evolution. | Business | Jian-Zhou Zhao, Hilda L. Collins, Jun Cao, Elizabeth D. Earle, Richard T. Roush, Anthony M. Shelton, Yaxin Li | |||
| Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype.(ribonucleic acid, embryonic stem) | Business | Tony Pawson, Janet Rossant, Tilo Kunath, Gerald Gish, Heiko Lickert, Nina Jones | |||
| UK farm-scale evaluations of transgenic herbicide-tolerant crops. | Business | David A. Andow | |||
| Ultrafast DNA sequencing. | Business | Jim Kling | |||
| Unlocking the money-making potential of RNAi.(RNA interferene ) | Business | Ken Howard | |||
| US FDA approves new class of HIV therapeutics.(Food and Drug Administration) | Business | Debra Robertson | |||
| US food aid still under GM cloud.(Genetically Modified) | Business | K.S. Jayaraman | |||
| US patent office strategic plan may penalize biotechs. | Business | Debra Robertson | |||
| Vox populi and public policy: why should we care? | Business | Henry I. Miller | |||
| Walking the drug regulatory tightrope.(includes related article) | Business | Alan Dove | |||
| Who is driving biotechnology acceptance? | Business | Nicholas Kalaitzandonakes, Jos Bijman | |||
| Widespread occurrence of antisense transcription in the human genome. | Business | Rodrigo Yelin, Dvir Dahary, Rotem Sorek, Erez Y. Levanon, Orly Goldstein, Avi Shoshan, Alex Diber, Sharon Biton, Yael Tamir, Rami Khosravi, Sergey Nemzer, Elhanan Pinner, Shira Walach, Jeanne Bernstein, Kinneret Savitsky, Galit Rotman | |||
| Will we reap what biopharming sows?(Column) | Business | Henry I. Miller | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.